Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialAchim Rittmeyer, David R. Gandara, Fabrice Barlési et al.|The Lancet|2016Cited by 4.8k
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Nicholas J. Vogelzang, Joaquim Bellmunt et al.|Nature|2014Cited by 2.4k
T cells use two directionally distinct pathways for cytokine secretionMorgan Huse, Mark M. Davis, Björn F. Lillemeier et al.|Nature Immunology|2006Cited by 427